| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Product revenue | ||||||
- | - | - | 141 | 258 | - | |
Total revenue | ||||||
5,775 | 4,416 | 4,361 | 141 | - | - | |
Operating expenses | ||||||
Cost of product revenue | ||||||
3,815 | 2,765 | 880 | 51 | 123 | - | |
Research and development | ||||||
5,819 | 5,154 | 4,269 | 7,206 | 6,475 | 4,220 | |
Sales and marketing | ||||||
6,936 | 9,831 | 3,083 | 485 | 765 | - | |
General and administrative | ||||||
13,502 | 12,277 | 11,247 | 5,983 | 5,339 | 4,095 | |
Settlement of Tempesta Royalty License Agreement | ||||||
648 | - | - | - | - | - | |
Impairment of goodwill | ||||||
0 | 5,210 | 16,827 | - | - | - | |
Impairment of indefinite-lived intangible assets | ||||||
4,000 | 0 | 2,300 | - | - | - | |
Total operating expenses | ||||||
34,723 | 35,240 | - | - | - | - | |
Total operating expenses | ||||||
- | - | 38,608 | 13,727 | 12,703 | 8,315 | |
Loss from operations | ||||||
-28,948 | -30,823 | -34,247 | -13,585 | -12,445 | -8,315 | |
Interest expense | ||||||
5,730 | 2,628 | 1,209 | 985 | 3,317 | 345 | |
Other income (expense) | ||||||
80 | 315 | 88 | -11 | -27 | - | |
Change in fair value of financial instruments | ||||||
-1,009 | -331 | -695 | - | - | - | |
Gain on Valeant settlement | ||||||
- | 1,204 | - | - | - | - | |
Change in fair value of warrants | ||||||
- | - | - | 43 | 501 | -51 | |
Loss on extinguishment of debt | ||||||
-4,940 | -544 | -477 | -108 | - | - | |
Loss before income tax expense | ||||||
-38,529 | -32,146 | -35,149 | -14,733 | - | - | |
Income tax expense | ||||||
10 | - | -13,181 | - | - | - | |
Net loss | ||||||
-38,539 | -32,146 | -21,968 | -14,733 | -16,291 | -8,609 | |
Deemed dividend | ||||||
- | - | - | - | 346 | 646 | |
Net loss attributable to common shareholders | ||||||
-44,726 | -32,146 | - | - | - | - | |
Net income (loss) attributable to common shareholders | ||||||
- | - | - | - | -16,637 | -9,256 | |
Net loss per share, basic and diluted (in dollars per share) | ||||||
-9.01 | -153.27 | -7.59 | -1.35 | -2.70 | -3.24 | |
Weighted-average common shares outstanding, basic and diluted (in shares) | ||||||
4,965 | 209 | 2,895 | 10,951 | 6,153 | 2,854 | |
Product revenue, net | ||||||
Total revenue | ||||||
5,775 | 4,238 | 1,485 | - | - | - | |
Collaboration revenue | ||||||
Total revenue | ||||||
- | 177 | 2,876 | - | - | - | |
Accretion of Series A convertible preferred | ||||||
Deemed dividend | ||||||
894 | - | - | - | - | - | |
Series B convertible preferred stock | ||||||
Deemed dividend | ||||||
4,239 | - | - | - | - | - | |
Series B-1 convertible preferred stock | ||||||
Deemed dividend | ||||||
530 | - | - | - | - | - | |
Series 1 warrants | ||||||
Deemed dividend | ||||||
522 | - | - | - | - | - | |